Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Immunovia AB (publ)    IMMNOV   SE0006091997

IMMUNOVIA AB (PUBL) (IMMNOV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Immunovia publ : Invitation to presentation of Immunovia's interim report January-March 2018 on April 27, 2018

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2018 | 05:46pm CEST

Lund (Sweden) - Immunovia will publish the company's interim report for the period January-March 2018 on Friday, April 27, at 08:00 a.m. CET.

Immunovia invites to a teleconference (in English) for investors, analysts and media on April 27, at 3:30 - 4:30 p.m. CET. Mats Grahn, CEO will present Immunovia and comment on the interim report followed by a Q&A-session.

Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below from:

Telephone:

SE: +46856642662
BE: +3224040635
CH: +41225675548
DE: +4969222229046
DK: +4582333178
FR: +33170750725
NE: +31207168416
NO: +4723500254
UK: +442030089803
US: +16465025116

There will be an MP3-file available at Immunovia's webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/ (http://immunovia.com/investors/financial-reports/))) (http://immunovia.com/investors/financial-reports/)) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

For questions or interview bookings: [email protected]

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

###

http://news.cision.com/immunovia-ab/r/invitation-to-presentation-of-immunovia-s-interim-report-january-march-2018-on-april-27--2018,c2505751

http://mb.cision.com/Main/13121/2505751/829612.pdf

(c) 2018 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOVIA AB (PUBL)
04/25IMMUNOVIA PUBL : Invitation to presentation of Immunovia's interim report Januar..
AQ
04/12IMMUNOVIA PUBL : NYU School of Medicine joins PanFAM-1 prospective study for the..
AQ
04/04NASDAQ : Stockholm Welcomes Immunovia to the Main Market
AQ
04/03IMMUNOVIA PUBL : Kallelse till Årsstämma i Immunovia AB
AQ
03/26IMMUNOVIA PUBL : published prospectus in connection with the change of listing v..
AQ
03/26IMMUNOVIA PUBL : has been approved for listing on Nasdaq Stockholm
AQ
03/23IMMUNOVIA PUBL : launches new website today
AQ
03/22IMMUNOVIA AB (PUBL) : Edison Issues Outlook on Immunovia (IMMUNOV)
AC
03/12IMMUNOVIA PUBL : announces financial targets
AQ
02/16IMMUNOVIA PUBL : Spanish center Santiago de Compostela joins the largest ever pr..
AQ
More news
Financials ( SEK)
Sales 2018 27,2 M
EBIT 2018 -6,23 M
Net income 2018 -61,8 M
Finance 2018 106 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 81,2x
EV / Sales 2019 57,5x
Capitalization 2 314 M
Chart IMMUNOVIA AB (PUBL)
Duration : Period :
Immunovia AB (publ) Technical Analysis Chart | IMMNOV | SE0006091997 | 4-Traders
Technical analysis trends IMMUNOVIA AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Mats Peter Egon Grahn Chief Executive Officer
Karl Arne Krister Borrebaeck Chairman
Lotta Blomgren Operations Director
Hans Liljenborg Chief Financial Officer
Lars Bertil Christer Wingren Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOVIA AB (PUBL)51.79%271
SARTORIUS AG43.20%10 713
MYRIAD GENETICS, INC.-16.79%1 996
VAREX IMAGING CORP-8.31%1 408
DIRUI INDUSTRIAL CO LTD--.--%1 088
NH SPECIAL PURPOSE ACQTN 2ND CO LTD--.--%390